Clinical Trial Detail

NCT ID NCT03980041
Title Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Infinity Pharmaceuticals, Inc.
Indications

urethra transitional cell carcinoma

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

ureter transitional cell carcinoma

Therapies

Nivolumab

IPI-549 + Nivolumab

Age Groups: senior adult

No variant requirements are available.